...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus
【24h】

Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus

机译：重组H1N1病毒样颗粒疫苗在雪貂中引发针对2009年大流行H1N1流感病毒的保护性免疫

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The pandemic virus of 2009 (2009 H1N1) continues to cause illness worldwide, especially in younger age groups. The widespread H1N1 virus infection further emphasizes the need for vaccine strategies that are effective against emerging pandemic viruses and are not dependent on the limitations of traditional egg-based technology. This report describes a recombinant influenza virus-like particle (VLP) vaccine consisting of hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins of influenza A/California/04/2009 (H1N1) virus. Influenza H1N1 VLPs with a diameter of approximately 120 nm were released into the culture medium from Sf9 insect cells infected with recombinant baculovirus coexpressing HA, NA, and M1 proteins. Purified recombinant H1N1 VLPs morphologically resembled influenza virions and exhibited biological characteristics of influenza virus, including HA and NA activities. In the ferret challenge model, 2009 influenza H1N1 VLPs elicited high-titer serum hemagglutination inhibition (HI) antibodies specific for the 2009 H1N1 virus and inhibited replication of the influenza virus in the upper and lower respiratory tract tissues following A/Mexico/4482/09 (H1N1) virus challenge. Moreover, a single 15 mu g dose of H1N1 VLPs resulted in complete virus clearance in the ferret lung. These results provide support for the use of recombinant influenza VLP vaccine as an effective strategy against pandemic H1N1 virus
机译：2009年的大流行性病毒（2009 H1N1）继续在世界范围内引起疾病，尤其是在较年轻的人群中。广泛的H1N1病毒感染进一步强调了对有效应对新兴大流行病毒且不依赖于传统蛋基技术的局限性的疫苗策略的需求。本报告介绍了一种重组流感病毒样颗粒（VLP）疫苗，该疫苗由A / California / 04/2009（H1N1）流感病毒的血凝素（HA），神经氨酸酶（NA）和基质（M1）蛋白组成。将直径约为120 nm的H1N1流感VLP从感染了共表达HA，NA和M1蛋白的重组杆状病毒的Sf9昆虫细胞释放到培养基中。纯化的重组H1N1 VLP在形态上类似于流感病毒颗粒，并显示出流感病毒的生物学特征，包括HA和NA活性。在雪貂攻击模型中，A / Mexico / 4482/09之后，2009流感H1N1 VLP引发了针对2009 H1N1病毒的高滴度血细胞凝集抑制（HI）抗体，并抑制了流感病毒在上下呼吸道组织中的复制。 （H1N1）病毒挑战。此外，单剂15微克的H1N1 VLP可以在雪貂肺中完全清除病毒。这些结果为重组流感VLP疫苗作为对抗大流行H1N1病毒的有效策略提供了支持

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号